QSAR analysis of substituted benzylamino- and heterocyclylmethylamino- carbodithioate derivatives of 4-(3H)-quinazolinone using CoMFA and SCORE2.0

Chinese Science Bulletin

Volumn 52, Issue 23, 2007, Pages 3200-3206

  Liu, Feng ^a   Liu, ShiYing ^a   Liu, Yan ^b   Han, DaXiong ^b   Jiang, YuYang ^a   Cao, ShengLi ^c   Zhao, YuFen ^a,b  

^a TSINGHUA UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

^c CAPITAL NORMAL UNIVERSITY   (China)

Author keywords

Antifolate; FlexiDock; QSAR; SCORE; Thymidylate synthase

Indexed keywords

EID: 36849021027     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-007-0470-z     Document Type: Article

References (29)

1. Marriott J H, Neidle S, Matusiak Z, et al. Chemoenzymatic preparation of the novel antifolate thymidylate synthase inhibitor N-(4-{N-[(6S)-2-methyl-4- oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino} -benzoyl)-L-glutamic acid and its glutamyl cleavage product. J Chem Soc, Perkin Trans, 1999, 1: 1495
2. Kelland L R, Kimbell R, Hardcastle A, et al. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines. Eur J Cancer, 1995, 31A: 981-986
3. Jackman A L, Farrugia D C, Gibson W, et al. ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer, 1995, 31A: 1277-1282
4. Peters G J, Smitskamp-Wilms E, Smid K, et al. Determinants of activity of the antifolate thymidylate synthase inhibitors tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Cancer Res, 1999, 59: 5529-5535
5. Lewis N L, Scher R, Gallo J M, et al. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed. Cancer Chemoth Pharm, 2002, 50: 257-265
6. Bavetsias V, Clauss R, Henderson E A. Antifolate chemistry: Synthesis of 4-{N-[(6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl] -N-(prop-2-ynyl)amino}benzoic acid via a (propargyl)Co2(CO)6+ complex. Org Biomol Chem, 2003, 1: 1943-1946
7. McGuire J J. Anticancer antifolates: Current status and future directions. Curr Pharm Des, 2003, 9: 2593-2613
8. Hughes L R, Jackman J A L, Oldfield J. Quinazoline antifolate thymidylate synthase inhibitors: Alkyl, substituted alkyl, and aryl substituents in the C-2 position. J Med Chem, 1990, 33: 3060-3067
9. Cao S L, Feng Y P, Jiang Y Y. Synthesis and in vitro antitumor activity of 4(3H)-quinazolinone derivatives with dithiocarbamate side chains. Bioorg Med Chem Lett, 2005, 15: 1915-1917
10. Cao S L, Feng Y P, Zhang X L. Synthesis of substituted benzylamino- and heterocyclylmethylamino carbodithioate derivatives of 4-(3H)-quinazolinone and their cytotoxic activity. Arch Pharm Chem Life Sci, 2006, 339: 250-254
11. Liu S Y, Liu F, Yu X Q. The 3D-QSAR analysis of 4-(3H)-quinazolinone derivatives with dithiocarbamate side chains on thymidylate synthase. Bioorgan Medic Chem, 2006, 14: 1425-1430
12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods, 1983, 65: 55
13. Phan J, Koli S, Minor W. Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug. Biochemistry, 2001, 40: 1897
14. Clark M, III Cramer R D, Van Opdenbosch O N J. The Tripos force field. J Comput Chem, 1989, 10: 982-1012
15. Weiner S J, Kollman P A, Case D A. A new force field for molecular mechanical simulation of nucleic acids and proteins. J Am Chem Soc, 1984, 106: 765-784
16. Tripos: St. Louis MO. Details of the implementation are given in Sybyl6.5. Theory Manual, 1998, 69
17. 2-guided region selection for comparative molecular field analysis: A simple method to achieve consistent results. J Med Chem, 1995, 38: 1060
18. Tripos Inc. 1699 South Hanley Rd, St. Louis, MO, USA. Sybyl6.5 Manual, 1999
19. Judson R. Reviews in Computational Chemistry. Lipkowitz K B, Boyd D B, ed. New York: VCH Publishers, 1997. 10
20. Morris G M, Goodsell D S, Halliday R S. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem, 1998, 19: 1639
21. Cramer R D, III David R D, Patterson E. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc, 1988, 110: 5959-5967
22. Stahle L, Wold S, Ellis G P. Progress in Medicinal Chemistry. Amsterdom: Elsevier, 1988. 292
23. Solis F J, Wets R J B. Minimization by random search techniques. Math Oper Res, 1981, 6: 19-30
24. Bush B L, Jr Nachbar R B. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des, 1993, 7: 587-619
25. 3 nicotinic acetylcholine receptor. J Med Chem, 2003, 46: 2031-2048
26. Andrew R L. Molecular Modeling Principles and Applications. Dorchester: Henry Ling Ltd. Press, 2001. 695-702
27. Wang R X, Liu L, Lai L H. SCORE: A new empirical method for estimating the binding affinity of a protein-ligand complex. J Mol Model, 1998, 4: 379-394
28. Li C H, Ma X H, Chen W Z. The study of the scoring function in protein-protein docking. Acta Biophys Sin, 2003, 19: 47-52
29. Liu L, Wang X R, Lai L H. 3D-QSAR and pharmacophore modeling of growth hormone secretagogues. Acta Phys-Chim Sin, 1997, 13: 1090-1096